
Angkak; Beni-koji; Hong Qu; Hung-chu; Monascus; Red Koji; Red Leaven; Red Rice; Red yeast ; Zhitai; Zue Zhi Kang
Cholestin3 ™
Used in China as food and medicine for thousands of years, red yeast rice is the fermented product of the fungus, Monascus purpureus, grown on rice. It was first marketed as a dietary supplement in the United States by Pharmanex under the trade name Cholestin (1). The active constituent, monacolin K, is the same as lovastatin, an active ingredient in the cholesterol-lowering drug, Mevacor® (2).
A number of clinical trials have demonstrated effectiveness of red yeast rice preparations in reducing cholesterol levels in hyperlipidemic patients (3) (4) (5) (14) (15) (16) (17). But an extract of red yeast rice did not lower blood pressure in hypertensive patients (20).
Several preparations of red rice yeast contain citrinin, a toxic fermentation byproduct (6).
Components such as citrinin, monacolines and monankarin, and monascopyridines have been isolated from red yeast rice (10). Fermentation products are standardized to contain 0.4% 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. HMG-CoA reductase is the rate-limiting enzyme in endogenous cholesterol biosynthesis (1). The principal HMG-CoA reductase inhibitor is monacolin K, also known as lovastatin (11). Lovastatin is also an active ingredient in the cholesterol-lowering drug, Mevacor® (2).
Little is known about the absorption, metabolism and excretion of red rice yeast. Lovastatin is partially metabolized by Cytochrome P450 3A4 (9).
Reported: stomachache (3), heartburn, dizziness and flatulence (7), and several cases of myopathy (21)
Case: Anaphylaxis in a 26-year-old man cooking with red yeast rice has been reported (8). In addition, rhabdomyolysis in a 28-year-old renal transplant recipient has also been reported (12).
Case: A sixty-three year old woman developed severe hypertransaminasemia following use of Equisterol, an over-the-counter lipid-lowering product containing guggulsterol and red yeast rice extract, for six months. Her symptoms normalized after equisterol was discontinued (18).
Case: A 62-year-old woman developed severe hepatitis following use of red yeast rice capsules for approximately 4 months before admission. Her condition improved after discontinuing red yeast rice (19).
Huang CF, Li TC, Lin CC, et al. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil. 2007;14(3):438-40.
This study was conducted to determine the effectiveness of red yeast rice in lowering hypercholesterolemia. Seventy-nine patients with hypercholesterolemia (aged 23-65 years) were randomized to receive a twice-daily dose of 600 mg red yeast rice or placebo for 8 weeks. The reduction in low-density lipoprotein cholesterol levels, total cholesterol/high-density lipoprotein cholesterol, low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and apolipoprotein B/apolipoprotein A-I ratios was significantly greater in the treatment group compared to those who took placebo.
Red yeast rice may be an effective agent in reducing lipid ratios in patients with hypercholesterolemia.
Bottom Line: Red yeast rice appears to lower blood cholesterol and triglyceride levels with few side effects, but there is no evidence that it can treat cancer.
Little is known about the way red yeast rice works. One of its constituents, monacolin K, also known as lovastatin, is an active ingredient in the cholesterol-lowering drug, Mevacor®. The drug works by inhibiting an enzyme essential for the creation of cholesterol in the body; therefore it is assumed that red yeast rice works through a similar mechanism.
High Cholesterol:
This study was conducted to find out if red yeast rice can lower hypercholesterolemia. Seventy-nine patients with hypercholesterolemia (aged 23-65 years) were randomized to receive a twice-daily dose of 600 mg red yeast rice or placebo for 8 weeks. The reduction in low-density lipoprotein cholesterol levels, total cholesterol/high-density lipoprotein cholesterol, low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and apolipoprotein B/apolipoprotein A-I ratios was significantly greater in the treatment group compared to those who took placebo.
The U.S. Food and Drug Administration declared that the dietary supplement Cholestin, manufactured by Pharmanex, cannot be marketed as a dietary supplement because it contained the same active ingredient as Mevacor®, an approved prescription drug.